Abstract
Bone marrow stroma is damaged by chemotherapy and irradiation protocol. Bone marrow microenvironment supports haematopoiesis and comprises Mesenchymal Stem Cells (MSCs). Coinfusion of MSCs with hematopoietic stem cells (HSC) improves engraftment and accelerates haematopoietic recovery. Stroma-derived factor-1 (SDF-1) is a chemotactic factor which plays a crucial role in stem cell transplantation by enhancing the ability of HSC to engraft. In this study expression of SDF-1 in bone marrow MSCs and the level of Colony Forming Unit Fibroblast (CFU-F) were evaluated in 8 patients with Acute Myeloid leukemia (AML). Evaluation was done at diagnosis and after induction/consolidation chemotherapy before the onset of haematopoietic stem cell transplantation (HSCT). CFU-F frequency increases from diagnosis to remission. Nevertheless level of stromal derived factor-1 (SDF-1) transcripts in bone marrow MSCs of patients with AML stays low. Considering the role of SDF-1 in the homing of HSC, the consequences of SDF-1 deficiency observed in this study might be deleterious on the engraftment after HSCT and haematopoietic recovery. The whole result of this clinical study is an argument for MSC infusion to restore a normal level of SDF1 in the bone marrow microenvironment that could reduce hematopoietic toxicity of chemotherapy and improve HSC engraftment after HSCT.
Keywords: Acute myeloid leukemia, Bone marrow microenvironment, Chemo-radiotherapy, Engraftment and haematopoietic recovery, Hematopoietic stem cells transplantation, Mesenchymal stem cells, Stromal-derived factor-1 (SDF-1).
Current Pharmaceutical Biotechnology
Title:Innovative Cell Therapy in the Treatment of Serious Adverse Events Related to Both Chemo-Radiotherapy Protocol and Acute Myeloid Leukemia Syndrome: The Infusion of Mesenchymal Stem Cells Post-Treatment Reduces Hematopoietic Toxicity and Promotes Hematopoietic Reconstitution
Volume: 14 Issue: 9
Author(s): Loic Fouillard, Sabine Francois, Sandrine Bouchet, Morad Bensidhoum, Abdelatif Elm’selmi and Alain Chapel
Affiliation:
Keywords: Acute myeloid leukemia, Bone marrow microenvironment, Chemo-radiotherapy, Engraftment and haematopoietic recovery, Hematopoietic stem cells transplantation, Mesenchymal stem cells, Stromal-derived factor-1 (SDF-1).
Abstract: Bone marrow stroma is damaged by chemotherapy and irradiation protocol. Bone marrow microenvironment supports haematopoiesis and comprises Mesenchymal Stem Cells (MSCs). Coinfusion of MSCs with hematopoietic stem cells (HSC) improves engraftment and accelerates haematopoietic recovery. Stroma-derived factor-1 (SDF-1) is a chemotactic factor which plays a crucial role in stem cell transplantation by enhancing the ability of HSC to engraft. In this study expression of SDF-1 in bone marrow MSCs and the level of Colony Forming Unit Fibroblast (CFU-F) were evaluated in 8 patients with Acute Myeloid leukemia (AML). Evaluation was done at diagnosis and after induction/consolidation chemotherapy before the onset of haematopoietic stem cell transplantation (HSCT). CFU-F frequency increases from diagnosis to remission. Nevertheless level of stromal derived factor-1 (SDF-1) transcripts in bone marrow MSCs of patients with AML stays low. Considering the role of SDF-1 in the homing of HSC, the consequences of SDF-1 deficiency observed in this study might be deleterious on the engraftment after HSCT and haematopoietic recovery. The whole result of this clinical study is an argument for MSC infusion to restore a normal level of SDF1 in the bone marrow microenvironment that could reduce hematopoietic toxicity of chemotherapy and improve HSC engraftment after HSCT.
Export Options
About this article
Cite this article as:
Fouillard Loic, Francois Sabine, Bouchet Sandrine, Bensidhoum Morad, Elm’selmi Abdelatif and Chapel Alain, Innovative Cell Therapy in the Treatment of Serious Adverse Events Related to Both Chemo-Radiotherapy Protocol and Acute Myeloid Leukemia Syndrome: The Infusion of Mesenchymal Stem Cells Post-Treatment Reduces Hematopoietic Toxicity and Promotes Hematopoietic Reconstitution, Current Pharmaceutical Biotechnology 2013; 14 (9) . https://dx.doi.org/10.2174/1389201014666131227120222
DOI https://dx.doi.org/10.2174/1389201014666131227120222 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles
Anti-Cancer Agents in Medicinal Chemistry New Therapies in SLE
Recent Patents on Inflammation & Allergy Drug Discovery Alkylating Agents, the Road Less Traversed, Changing Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry STAT-1 and STAT-3: Closely Related Transcription Factors with Antagonistic Effects on Cell Proliferation and Apoptosis
Current Genomics TGF-β1 Signalling, Connecting Aberrant Inflammation and Colorectal Tumorigenesis
Current Pharmaceutical Design Phosphoproteomics as a Promising Tool for Broadening the Analysis of Clinical Samples and for the Fight Against Cancer Disease
Current Pharmaceutical Analysis Detecting Growing Mammary Tumors with Monoclonal Antibodies Against Vascular Endothelial Growth Factor Receptor – 3
Current Radiopharmaceuticals New Approaches With Natural Product Drugs for Overcoming Multidrug Resistance in Cancer
Current Pharmaceutical Design p53 Gene Family: Structural, Functional and Evolutionary Features
Current Genomics ATP Site-Directed Inhibitors of Protein Kinase CK2: An Update
Current Topics in Medicinal Chemistry Production, Novel Assay Development and Clinical Applications of Monoclonal Antibodies
Recent Patents on Anti-Cancer Drug Discovery Heat Shock Protein 90 Inhibitors in Oncology
Current Proteomics The Anticancer Face of Interferon Alpha (IFN-Alpha): From Biology to Clinical Results, with a Focus on Melanoma
Current Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Glioma Stem Cell Maintenance: The Role of the Microenvironment
Current Pharmaceutical Design Nitric Oxide: Cancer Target or Anticancer Agent?
Current Cancer Drug Targets Application of Gene Therapy in Diabetes Care
Infectious Disorders - Drug Targets Unravelling the Role of Infectious Agents in the Pathogenesis of Human Autoimmunity: The Hypothesis of the Retroviral Involvement Revisited
Current Molecular Medicine Culture Supernatants from Lactobacillus plantarum Induce Necrosis on a Human Promyelocytic Leukemia Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets HIV Shedding in Cervico-Vaginal Secretions in Pregnant Women
Current HIV Research